Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity (Q51815934)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 August 2009

Language	Label	Description	Also known as
English	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity	scientific article published on 10 August 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J-H Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

J-H Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

S-N Lim

3

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

D-Y Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

S H Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

Y-S Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

Y-A Kang

7

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

S-I Kang

8

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

M J Jeon

9

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

M Seol

10

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

E-J Seo

11

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

H S Chi

12

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

C J Park

13

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

S Jang

14

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

S-C Yun

15

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

K-H Lee

16

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

language of work or name

0 references

publication date

10 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

45

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

3

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

450-457

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

Myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Bone marrow transplantation for myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Allogeneic transplantation for myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Allogeneic stem cell transplantation for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

21 January 2018

Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of differe

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.190

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2009.190

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19668236

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51815934&oldid=2283246848"